ClinicalTrials.gg
SuspendedNCT04104321ARMORUpdated Feb 11, 2026Results posted

A Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects With NASH (ARMOR)

A Phase 3 interventional study of Aramchol free acid and Placebo in Nonalcoholic Steatohepatitis (NASH), sponsored by Galmed Research and Development, Ltd.. Suspended at 2 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by Galmed Research and Development, Ltd. · Phase 3, Interventional, and Treatment

How we know

Why this study was suspended
Interim analysis results from the open-label part of the study. The double blind portion of the study will be resumed once the study will continue.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
157
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Enrollment
107th of 460
157 · median 56
Started
2019
with 61 others
Phase 3
29 of 547
7 open now
Registered
310th of 547
by date

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 107th largest by enrollment of the 460 interventional ones that give a count, is one of 62 that started in 2019, is one of 29 in phase 3, and was the 310th registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

An Open-Label Part was added:

This part will enroll in selected sites which are less affected by the COVID-19 pandemic.

150 subjects with NASH and fibrosis confirmed by liver histology (F1-F3) will be randomized into 3 groups according to the post-baseline biopsy.

The objective of the Open-Label Part is:

  • To evaluate the safety and PK of twice daily administration (BID) of Aramchol 300mg in subjects with NASH and liver fibrosis.
  • To explore the kinetics of histological outcome measures and Non-Invasive Tests (NITs) associated with NASH and fibrosis for the treatment duration of 24, 48 and 72 weeks.

All patients will be allocated to Aramchol.

Double Blind Part:

This part is double blind, placebo controlled randomized in subjects with NASH and fibrosis stages 2-3 who are overweight or obese and have prediabetes or type 2 diabetes.

The primary objectives of this part of the study are to evaluate the effect of Aramchol as compared to placebo on NASH resolution, fibrosis improvement and clinical outcomes related to progression of liver disease.

Subjects will be randomized to receive Aramchol 300mg BID or matching placebo in a 2:1 randomization ratio.

This double-blind phase of the study will recruit patients once the study will be continued.

Read the detailed description

A total of 150 subjects, including those already randomized to Aramchol 300 mg BID or Placebo, were to be randomized in a ratio of 1:1:1 to receive Aramchol 300 mg BID in the open-label (OL) part according to the grouping below:

Group A: The post-baseline liver biopsy was to be conducted at Week 24 Group B: The post-baseline liver biopsy was to be conducted at Week 48 Group C: The post-baseline liver biopsy was to be conducted at Week 72

In order to more comprehensively explore the kinetics of histological outcome measures (e.g., are there subjects who did not show improvement in outcome at Weeks 24, 48, or 72, but improved with longer duration of treatment), a second post-baseline liver biopsy sample was to be collected for subjects whose post-baseline liver biopsy at Weeks 24 or 48, or 72 did not show at least one stage improvement in fibrosis (fibrosis non-responders). The second post-baseline liver biopsy sample was to be collected one year later (i.e., at Weeks 72 or 96 or 120, respectively).

Subjects already randomized and ongoing in the PC part were given the option to switch to the OL part

03

Conditions studied

  • Nonalcoholic Steatohepatitis (NASH)

Keywords

  • fibrosis
  • liver fibrosis
  • diabetes
  • obesity
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Male or female age 18 to 75 years
  2. Histological confirmation of NASH on a diagnostic liver by central reading of the slides (biopsy obtained within 6 months prior to randomization or during the screening period)
  3. Total NAS Score 4 or more with at least 1 in each component of the NAS Score (steatosis ≥1 AND inflammation ≥1 AND ballooning ≥1)
  4. Fibrosis Stage must be 2 or 3 (Open-Label Part may include up to 30 subjects with fibrosis stage 1)
  5. (BMI) between 25kg/m2 and 40 kg/m2 (Open Label part: BMI \<40 kg/m2)
  6. >20 IU/L
  7. Type 2 diabetes mellitus or prediabetes (Open Label Part only: Type 2 diabetes or prediabetes is not an inclusion criteria)
  8. For subjects with type 2 diabetes, glycemia must be controlled
  9. Females of must practice a highly effective method of throughout the study period and for 1 month after treatment discontinuation.
  10. Able to understand the nature of the study and to provide signature of the written .

Key Exclusion Criteria:

  1. documented liver cirrhosis (fibrosis stage 4)
  2. Inability or unwillingness to undergo a liver biopsy
  3. Abnormal synthetic liver function
  4. ALT or AST >5× (ULN)
  5. count \< 150,000mm3
  6. Alkaline phosphatase ≥2× ULN
  7. Known or suspected hepatocellular carcinoma (HCC)
  8. Model for End-Stage Liver Disease (MELD) score > 12
  9. Prior history or presence of decompensated liver disease
  10. Other (acute or chronic) coexisting liver disease based on medical history and/or centralized review of liver histology)
  11. Known alcohol and/or any other drug abuse or dependence in the last five years
  12. Weight loss of more than 5% within 3 months prior to screening
  13. History of bariatric surgery within 5 years of liver biopsy or planned surgery for weight reduction
  14. Treatment with drugs that may cause NAFLD within 12 months prior to liver biopsy
  15. Treatment with some anti-diabetic medications; Unless started prior to biopsy (timeframe depending on drug) and stable
  16. Current or planned treatment with drugs
  17. Evidence of any other unstable or untreated disease
  18. Uncontrolled hypertension
  19. Any other condition that in the opinion of the Investigator warrants exclusion from the study
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
157 participants (actual)

Study arms

  • Experimental
    Aramchol free acid

    Aramchol 300 mg oral tablet

    Drug: Aramchol free acid

  • Placebo comparator
    Placebo

    Placebo matching oral tablet

    Drug: Placebo

Interventions

  • DrugAramchol free acid

    Aramchol 300 mg BID

    Also known as: Two tablets of Aramchol free acid

  • DrugPlacebo

    Placebo BID

    Also known as: Two tablet of Aramchol matching placebo

06

What researchers measure

Primary outcomes

  1. Open Label Part: Improvement of Fibrosis Based on Liver Biopsy

    Improvement of fibrosis was defined by the following: 1. One stage or more reduction in fibrosis stage as assesed by the NASH-CRN classification 2. Ranked paired assessment between post-baseline compared to baseline biopsies (i,proved, worsened or stable fibrosis) 3. Reduction in the the continous phenotypic Fibrosis composite severity (Ph-FCS) score ≥0.3 in absolute value or ≥25% in relative value

    Time frame: Up to 72 or 120 weeks

  2. Double Blind Part: To Evaluate the Effect of Aramchol Compared to Placebo on Liver Histology by Assessing the Following Primary Endpoints. Study Was Suspended and Thus Results Are Expected 2027

    * Resolution of NASH defined as the Proportion (%) of subjects with resolution of NASH (defined by Ballooning of 0 and inflammation 0-1) and no worsening of liver fibrosis, or * Improvement in Fibrosis defined as the Proportion (%) of subjects with improvement in liver fibrosis greater than or equal to one stage and no worsening of steatohepatitis.

    Time frame: 72 weeks

  3. Double Blind Part: To Evaluate the Effect of Aramchol Compared to Placebo on Composite Long-term Outcome Study Was Suspended so Results Expected 2027

    Proportion (%) of subjects experiencing at least 1 of the following events: All-cause mortality, Liver transplant, Histological progression to cirrhosis, MELD score \>15, Hospitalization due to hepatic decompensation event(s).

    Time frame: at End of Study, latest at 5 years from last subject's randomization

07

Results

Posted Dec 16, 2024

Participant flow

Participant flow — Overall Study
MilestoneARCON ITT
Started157
Subjects randomized to the ol part, received aramchol and had baseline and post-baseline biopsy51
Completed154
Not completed3
Withdrew: Didn't take the study drug3

Outcome measures

PrimaryOpen Label Part: Improvement of Fibrosis Based on Liver Biopsy

Improvement of fibrosis was defined by the following: 1. One stage or more reduction in fibrosis stage as assesed by the NASH-CRN classification 2. Ranked paired assessment between post-baseline compared to baseline biopsies (i,proved, worsened or stable fibrosis) 3. Reduction in the the continous phenotypic Fibrosis composite severity (Ph-FCS) score ≥0.3 in absolute value or ≥25% in relative value

Time frame:
Up to 72 or 120 weeks
Reported as:
Number · percentage of participants improving
Open Label Part: Improvement of Fibrosis Based on Liver Biopsy
percentage of participants improvingAramchol
Fibrosis improvement NASH-CRN≥1 stage31.4 (19.1 to 45.9)
NASH resolution without worsening of fibrosis26.5 (14.9 to 37.5)
Fibrosis improvement by ranked assessment51.0 (36.6 to 65.2)
Fibrosis improvement (absolute FCS score reduction ≥0.374.5 (60.4 to 85.7)
Fibrosis improvement (relative FCS reduction by ≥25% AI cutoff)41.2 (27.6 to 55.8)
PrimaryDouble Blind Part: To Evaluate the Effect of Aramchol Compared to Placebo on Liver Histology by Assessing the Following Primary Endpoints. Study Was Suspended and Thus Results Are Expected 2027

* Resolution of NASH defined as the Proportion (%) of subjects with resolution of NASH (defined by Ballooning of 0 and inflammation 0-1) and no worsening of liver fibrosis, or * Improvement in Fibrosis defined as the Proportion (%) of subjects with improvement in liver fibrosis greater than or equal to one stage and no worsening of steatohepatitis.

Time frame:
72 weeks

Results for this outcome have not been posted.

PrimaryDouble Blind Part: To Evaluate the Effect of Aramchol Compared to Placebo on Composite Long-term Outcome Study Was Suspended so Results Expected 2027

Proportion (%) of subjects experiencing at least 1 of the following events: All-cause mortality, Liver transplant, Histological progression to cirrhosis, MELD score \>15, Hospitalization due to hepatic decompensation event(s).

Time frame:
at End of Study, latest at 5 years from last subject's randomization

Results for this outcome have not been posted.

Adverse events

Collected over Up to 124 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Patients Randomized to the OL Part of the ARMOR Study154/154 (100%)1/154 (0.6%)27/154 (17.5%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventPatients Randomized to the OL Part of the ARMOR Study
coronary artery diseaseCardiac disorders1/154
Coronary artery stenosisCardiac disorders1/154
Retinal detachmentEye disorders1/154
Non-cardiac chest painGeneral disorders1/154
Cholecystitis acuteHepatobiliary disorders1/154
Cholecystitis chronicHepatobiliary disorders1/154
COVID-19Infections and infestations1/154
COVID-19 pneumoniaInfections and infestations1/154
PneumoniaInfections and infestations1/154
Lumbar vertebral fractureInjury, poisoning and procedural complications1/154
Most frequent other events
Most frequent other events
EventPatients Randomized to the OL Part of the ARMOR Study
COVID-19Infections and infestations27/154
HeadacheNervous system disorders12/154
HypertensionCardiac disorders10/154
Back painMusculoskeletal and connective tissue disorders9/154
ConstipationGastrointestinal disorders8/154
NauseaGastrointestinal disorders8/154
Procedural painSurgical and medical procedures8/154

Baseline characteristics

All patients who were randomized to Aramchol

Age, Continuous
Age, Continuous(Years)ARCON ITT
Mean58.1 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)ARCON ITT
Female119
Male38
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ARCON ITT
Hispanic or Latino28
Not Hispanic or Latino127
Unknown or Not Reported2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ARCON ITT
American Indian or Alaska Native0
Asian15
Native Hawaiian or Other Pacific Islander2
Black or African American4
White134
More than one race1
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(participants)ARCON ITT
United States84
Turkey25
South Korea10
Mexico7
Chile6
Spain5
France5
Canada5
Australia4
Belgium3
Israel2
United Kingdom1
Weight (kg)
Weight (kg)(Kg)ARCON ITT
Mean89 ± 15.2
Body mass index (kg/m2)
Body mass index (kg/m2)(Kg/ M2)ARCON ITT
Mean32.7 ± 4.2
Biopsy evaluation based on NASH CRN
Biopsy evaluation based on NASH CRN(Participants)ARCON ITT
Baseline CRN fibrosis stage- F133
Baseline CRN fibrosis stage- F234
Baseline CRN fibrosis stage- F376
Baseline CRN fibrosis stage- F48
Not reported6

1 further baseline measures are reported on the registry.

08

Study locations

2 sites
  • The Public Health Trust of Miami-Dade County, Florida, dba the Jackson Health System
    Miami, Florida 33136, United States
  • Texas Clinical Research Institute, LLC
    Arlington, Texas 76012, United States
09

References and documents

Publications

  • Ratziu V, Yilmaz Y, Lazas D, Friedman SL, Lackner C, Behling C, Cummings OW, Chen L, Petitjean M, Gilgun-Sherki Y, Gorfine T, Kadosh S, Eyal E, Sanyal AJ. Aramchol improves hepatic fibrosis in metabolic dysfunction-associated steatohepatitis: Results of multimodality assessment using both conventional and digital pathology. Hepatology. 2025 Mar 1;81(3):932-946. doi: 10.1097/HEP.0000000000000980. Epub 2024 Jun 25. PubMed 38916482 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2019 to primary completion in Dec 2022, 38 months.

Results were first posted in Dec 2024, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2019
First posted
Sep 26, 2019
StartActual
Sep 23, 2019
Primary completionActual
Dec 8, 2022
CompletionEst.
Jun 30, 2027
Results first posted
Dec 16, 2024
Last update
Feb 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04104321
Lead sponsor
Galmed Research and Development, Ltd.
Responsible party
Sponsor
First posted
Sep 26, 2019
Start date
Sep 23, 2019
Primary completion
Dec 8, 2022
Completion
Jun 30, 2027 (estimated)
Results posted
Dec 16, 2024
Last update
Feb 11, 2026

Study contacts

Yossi Gilgun-Sherki, PhD, MBA
study director · Executive Drug Development Consultant

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion